Revance Therapeutics reported $17.18M in Stock for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Stock Change
Aerie Pharmaceuticals AERI:US USD 46.76M 245K
ALKERMES ALKS:US USD 166.3M 10.69M
Bristol Myers Squibb BMY:US USD 2.07B 68M
Cara Therapeutics CARA:US USD 1.84M 1.62M
Coherus Biosciences CHRS:US USD 27.72M 4.02M
Eli Lilly And LLY:US USD 3.83B 68.3M
Endo International Ordinary Shares ENDP:US USD 288.91M 1.16M
Horizon Pharma HZNP:US USD 190.26M 13.42M
JAZZ PHA JAZZ:US USD 728.07M 133.63M
Neurocrine Biosciences NBIX:US USD 37M 7.7M
Pacira Pharmaceuticals PCRX:US USD 96.8M 3.79M
Procter & Gamble PG:US USD 7.59B 666M
Revance Therapeutics RVNC:US USD 17.18M 3.58M
Supernus Pharmaceuticals SUPN:US USD 83.16M 1.69M
Teva Pharmaceutical Industries TEVA:US USD 3.86B 190M